Thought Leadership
Email Page
FDA Extends Enforcement Discretion Period for Regenerative Medicine Products, but This Isn't a Green Light for Bad Actors
August 6, 2020
Chad Landmon and Michelle Divelbiss
Cell & Gene

Axinn partner Chad Landmon and associate Michelle Divelbiss authored the Cell & Gene article, "FDA Extends Enforcement Discretion Period for Regenerative Medicine Products, but This Isn't a Green Light for Bad Actors."

Click here to access the article.